Sir Richard Sykes, Former Glaxo Wellcome Chairman, CEO and GlaxoSmithKline Chairman, Agrees to Join the Abraxis BioScience Board of Directors

SCHAUMBURG, Ill. and SANTA MONICA, Calif., Dec. 20

Dec 20, 2005, 00:00 ET from American Pharmaceutical Partners, Inc.

/PRNewswire-FirstCall/ -- American Pharmaceutical Partners, Inc.
 (Nasdaq:   APPX)(APP), and American BioScience, Inc. (ABI) today announced that
 Sir Richard Sykes, former Chairman and Chief Executive Officer of Glaxo
 Wellcome plc and Chairman of the Board of GlaxoSmithKline plc, has agreed to
 join the Board of Directors of Abraxis BioScience, Inc. following the
 consummation of the proposed merger between APP and ABI (APP will be renamed
 Abraxis BioScience following the merger).  Sir Richard currently serves as
 Rector of the largest applied science and technology university in the United
 Kingdom, the Imperial College of Science, Technology and Medicine at the
 University London.
     In November, APP and ABI announced the signing of a definitive merger
 agreement which will merge the companies to create Abraxis BioScience, a fully
 integrated, global biopharmaceutical company.  The transaction is expected to
 close in the first half of 2006.  The Abraxis BioScience board will consist of
 a majority of independent directors, including current APP board members.
     Patrick Soon-Shiong, M.D., chairman and CEO of APP, ABI and Abraxis
 BioScience said Sir Richard is an important addition to the Abraxis BioScience
 Board.  "Our goal in assembling the new Abraxis BioScience Board is to bring
 together directors who will bring vision, experience and expertise to guide
 management as Abraxis BioScience evolves into a global biotechnology company
 pursuing therapies for true unmet medical needs," he said.  "Sir Richard's
 international stature and experience in building a world-class company in
 GlaxoSmithKline and his ongoing involvement with institutions committed to the
 pursuit of breakthrough, next generation technologies will be invaluable to
 our company.  We are thrilled and honored to have him join our board."
     Sir Richard Sykes stated, "The science that Patrick and his team are
 pursuing in oncology, nanotechnology and tumor secreted proteins such as SPARC
 could very well change the way cancer and other diseases are treated.  The
 results they have achieved to date are both impressive and exciting.  The
 combination of APP and ABI has created an infrastructure with all the
 ingredients necessary to be an integrated leading biopharmaceutical
 organization developing important therapies in oncology and critical care.
 Over the next two decades, technological advances will lead to a whole range
 of new ways of managing diseases from diagnosis to cure.  I believe that the
 structure of our industry will have to adapt if we are to fully recognize the
 potential of the new technologies and I am pleased to have been asked to
 contribute to this effort."
     Sir Richard was appointed Deputy Chairman and Chief Executive of Glaxo in
 March 1993.  He led Glaxo's acquistion of Wellcome in 1995 and was a principal
 architect of Glaxo Wellcome's merger with SmithKline Beecham to form
 GlaxoSmithKline at the end of 2000.  He stood down as Chairman of
 GlaxoSmithKline plc in May 2002 to continue his role as Rector of Imperial
 College London.
     Sir Richard initially joined Glaxo Research Limited in 1972 as Head of the
 Antibiotic Research Unit.  In 1979, he became Director of Microbiology and an
 Associate Director of The Squibb Institute for Medical Research, Princeton,
 New Jersey.  He served as Vice President, Infectious and Metabolic Diseases
 there from 1983 to 1986.  Sir Richard again joined Glaxo in the UK as Deputy
 Chief Executive of Glaxo Group Research Ltd and was appointed Group Research
 and Development Director, Glaxo plc and Chairman & Chief Executive of Glaxo
 Group Research Limited in 1987.  He was named Deputy Chairman & Chief
 Executive of Glaxo plc in March 1993 and Chairman & Chief Executive of Glaxo
 Wellcome plc in May 1997.
     Sir Richard received his knighthood in the 1994 New Year Honours list for
 services to the pharmaceutical industry.  He sits on a number of government
 and scientific committees and is a Trustee of the Natural History Museum in
 London.  Sir Richard was appointed Chairman of the Bioscience Leadership
 Council in November 2003.  Sir Richard has recently accepted the role of Chair
 of the WHO International Advisory Board which oversees the International
 Clinical Trials Registry Platform.  He is currently Chairman of the Biomedical
 Sciences International Council, Singapore, and a board member of Rio Tinto
 Limited and the Lonza Group Limited.  He also serves as healthcare advisor to
 Apax Partners Limited.
     He served as President of the British Association for the Advancement of
 Science, 1998-1999, and holds a number of honorary degrees and awards from
 institutions both in the UK and overseas.  He is a Fellow of the Royal
 Society, an Honorary Fellow of the Royal Society of Chemistry and a Fellow of
 the Academy of Medical Sciences.  He is a Fellow of Imperial College School of
 Medicine, King's College, London, a Fleming Fellow at Lincoln College, Oxford,
 an Honorary Fellow of the Royal College of Physicians, an Honorary Fellow of
 the University of Wales, Cardiff and an Honorary Fellow of the University of
 Central Lancashire.  Sir Richard was awarded a PhD in Microbial Biochemistry
 from Bristol University and a DSc from the University of London.
     About American BioScience, Inc.
     American BioScience, Inc. is a privately held biotechnology company
 focused on the discovery, development and delivery of next-generation
 therapeutics including biologically active molecules already existing within
 the human biological system, for the treatment of life-threatening diseases.
 ABI owns a majority interest in American Pharmaceutical Partners, Inc.
     About American Pharmaceutical Partners, Inc.
     American Pharmaceutical Partners, Inc. is a specialty drug company that
 develops, manufactures and markets injectable pharmaceutical products,
 focusing on the oncology, anti-infective and critical care markets.  Abraxis
 Oncology, the proprietary division of APP, is devoted entirely to developing
 and promoting innovative, next-generation cancer therapies such as
 ABRAXANE(R), recently launched for the treatment of metastatic breast cancer.
 For more information, visit APP's website at and
     Forward-looking statements in this document include statements regarding
 our expectations, beliefs, hopes, goals, intentions, initiatives or
 strategies, including statements regarding the expected time of completion of
 the merger and the benefits of the merger, including the creation of an
 integrated, global biopharmaceutical leader and Sir Richard Sykes joining the
 board of the combined company.  Because these forward-looking statements
 involve risks and uncertainties, there are important factors that could cause
 actual results to differ materially from those in the forward-looking
 statements.  These factors include, without limitation, unexpected delays in
 consummation of the merger, if at all, adverse market reactions to the
 proposed merger, failure of the benefits of the merger to materialize,
 difficulties in integrating the businesses and operations of the two
 companies, and the fact that Sir Richard Skyes is not obligated to join the
 board of the combined company.  Relevant information concerning risks can be
 found in APP's Form 10-K for the year ended December 31, 2004 and other
 documents filed by us with the Securities and Exchange Commission.
     Contacts:  American Pharmaceutical Partners, Inc.
                Nicole Williams
                Executive Vice President & CFO
                (847) 969-2700
                PondelWilkinson Inc.
                Rob Whetstone/Robert Jaffe
                (310) 279-5963

SOURCE American Pharmaceutical Partners, Inc.